Drugs / Amuvatinib
Amuvatinib
also known as
MP-470 · AMUVATINIB HYDROCHLORIDE · HPK 56 · HPK56 HCL · MP-470 HCI · MP-470 HYDROCHLORIDE · MP-470.HCL
Small molecule targets FLT3, KIT, MET, PDGFRA, RAD51 via inhibition
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00881166 | Nov 2007 → Dec 2009 | cancer | Astex Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00894894 | May 2007 → Dec 2008 | cancer | Astex Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01357395 | May 2011 → May 2012 | small cell lung carcinoma | Astex Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT00504205 | May 2007 → Dec 2008 | cancer of unknown primary site, lymphoma | Astex Pharmaceuticals, Inc. | Terminated | No outcome recorded |
Evidence & citations 16 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Amuvatinib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01357395 ↗ |
| Known as | AMUVATINIB HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL2103851 ↗ |
| Known as | HPK 56 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2103851 ↗ |
| Known as | HPK56 HCL | ChEMBL registry synonym — accepted as the source's own label CHEMBL2103851 ↗ |
| Known as | MP-470 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00894894 ↗ |
| Known as | MP-470 HCI | ChEMBL registry synonym — accepted as the source's own label CHEMBL2103851 ↗ |
| Known as | MP-470 HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL2103851 ↗ |
| Known as | MP-470.HCL | ChEMBL registry synonym — accepted as the source's own label CHEMBL2103851 ↗ |
| Action | Inhibit | “MP470 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.” NCT00504205 ↗3“Platelet-derived growth factor receptor alpha inhibitor” CHEMBL2103851 ↗ “Tyrosine-protein kinase receptor FLT3 inhibitor” CHEMBL2103851 ↗ “Hepatocyte growth factor receptor inhibitor” CHEMBL2103851 ↗ |
| Modality | Small molecule | — CHEMBL2103851 ↗ |
| Route | Oral | “Patients receive oral multitargeted receptor tyrosine kinase inhibitor MP470 until the maximum tolerated dose is determined.” NCT00504205 ↗ |
| Target | FLT3 | “Tyrosine-protein kinase receptor FLT3 inhibitor” CHEMBL2103851 ↗ |
| Target | KIT | “in vitro pharmacological activity against mutant KIT, platelet-derived growth factor receptor alpha (PDGFRα), and Rad51” PMID 23178951 ↗ Nov 2012 |
| Target | MET | “Hepatocyte growth factor receptor inhibitor” CHEMBL2103851 ↗ |
| Target | PDGFRA | “Platelet-derived growth factor receptor alpha inhibitor” CHEMBL2103851 ↗ |
| Target | RAD51 | “in vitro pharmacological activity against mutant KIT, platelet-derived growth factor receptor alpha (PDGFRα), and Rad51” PMID 23178951 ↗ Nov 2012 |